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3 
Abstract  39 
Mesenchymal stromal cells (MSCs) have recently been shown to play important roles in 40 
mammalian host defenses against intracellular pathogens, but the molecular mechanism still 41 
needs to be clarified. We confirmed that human MSCs (hMSCs) pre-stimulated with IFN-γ 42 
showed a significant and dose-dependent ability to inhibit the growth of two types of 43 
Toxoplasma gondii (type I strain RH/GFP or type II strain PLK/RED). However, in contrast 44 
to previous reports, the anti-T. gondii activity of hMSCs was not mediated by indoleamine 45 
2,3-dioxygenase (IDO). Genome-wide RNA-seq analysis revealed that IFN-γ increased the 46 
expression of the p65 family of guanylate-binding proteins (hGBPs) in hMSCs, especially 47 
hGBP1. To analyze the functional role of hGBPs, stable knockdowns of hGBP1, -2, -5 in 48 
hMSCs were established using a lentiviral transfection system. hGBP1 knockdown in hMSCs 49 
resulted in a significant loss of the anti-T. gondii host defense property, compared with 50 
hMSCs infected with non-targetted control sequences. hGBP2 and -5 knockdowns had no 51 
effect. Moreover, the hGBP1 accumulation on the parasitophorous vacuole (PV) membranes 52 
of IFN-γ-stimulated hMSCs might protect against T. gondii infection. Taken together, our 53 
results suggest that hGBP1 plays a pivotal role in anti-T. gondii protection of hMSCs and 54 
may shed new light on clarifying the mechanism of host defense properties of hMSCs. 55 
56 
4 
Significance  57 
Mesenchymal stem cells (MSCs) are thought to be derived from pericytes and exhibit a 58 
cellular, autonomous antimicrobial effector function which provides therapeutic potential 59 
against infectious diseases. However, the molecular mechanism remains unknown. Here, we 60 
demonstrate that human guanylate-binding protein 1 (hGBP1) is a key protective factor 61 
against T. gondii infection in human MSCs (hMSCs). The recruitment of hGBP1 to the 62 
parasitophorous vacuole membrane in IFN-γ-stimulated hMSCs significantly inhibited T. 63 
gondii replication. Thus, our current study reveals an important function of hGBP1 in the 64 
defense against T. gondii and may shed new light on clarifying the mechanism of host 65 
defense properties of hMSCs. 66 
67 
5 
/body 68 
Mesenchymal stromal cells (MSCs) comprise a heterogeneous cell population endowed with 69 
multi-lineage differentiation potential and extensive immunomodulatory properties. MSCs 70 
have been successfully used to prevent and treat immune disorders, such as graft-versus-host 71 
disease, and emerging preclinical studies suggest that they might also protect against 72 
infectious challenges (1, 2). Recent studies showed that MSCs are located in the perivascular 73 
niche and constitute a subset of pericytes that are involved in both pathogen recognition and 74 
early inflammatory events (3). MSCs appear to impede pathogen growth and reduce the 75 
microbial burden by inhibiting growth through soluble factors or by enhancing the 76 
antimicrobial function of immune cells, as shown both in vitro and in vivo (2-5). For example, 77 
Nemeth et al. reported that mouse MSCs (mMSCs) prolonged the survival of septic mice and 78 
improved their organ (kidney, liver, and pancreas) functions (5). They did this by enhancing 79 
IL-10 production from murine alveolar macrophages via MSC-secreted cyclooxygenase-2 80 
(COX2) and prostaglandin E2 (PGE2) (5). Data from murine colitis models have shown that 81 
human adipose-derived MSCs protect against dextran-induced colitis by decreasing the 82 
secretion of pro-inﬂammatory cytokines and chemokines (6). However, the antimicrobial 83 
effector molecules in vertebrate MSCs are not universally the same (4-11). The antimicrobial 84 
effect of unstimulated hMSCs is mediated by the cathelicidin, LL-37 (4), as shown both in 85 
vitro and in vivo. In IFN-γ-stimulated hMSCs, by contrast, the antibacterial effect is mediated 86 
through the tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO) (9). 87 
Conﬂicting results are also reported in mouse, in which the decision as to whether mMSCs 88 
increase the activity of phagocytes or not depends on the origin of these cells (11).  89 
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Toxoplasma gondii is an obligatory intracellular protozoan parasite that infects virtually all 90 
warm-blooded vertebrates including humans. Clinical symptoms are rarely observed in most 91 
T. gondii-infected immunocompetent individuals. However, the parasite can cause severe 92 
disease and even death in immunosuppressed individuals, such as AIDS, cancer and organ 93 
transplantation patients. T. gondii can actively invade host cells in vitro by dividing within a 94 
nonfusogenic parasitophorous vacuole (PV), a membrane structure formed during invasion 95 
that is maintained to surround the intracellular replicating parasites. However, this activity 96 
may not be completed in vivo due to the innate resistance mechanisms in host cells and, 97 
especially, in those that are naturally resistant to T. gondii (12).  98 
During T. gondii infection, NK cells, neutrophils, CD4+ cells and CD8+ T cells can all 99 
release IFN-γ, which is the central regulator of the immune response against T. gondii (12-14). 100 
In mouse cells, the most important IFN-γ-inducible effectors against T. gondii are likely to 101 
include inducible nitric oxide synthase (iNOS) (15), reactive oxygen species (ROS) (16), 102 
immunity-related p47 GTPases (IRGs) (17), and GBPs (18). Mice lacking a fragment of 103 
chromosome 3 that encodes GBP1, -2, -3, -5, -7, and -2ps were highly susceptible to T. gondii 104 
infection even after stimulation of IFN-γ (18). This indicates the importance of GBPs in 105 
immunity to T. gondii and providing insight into the antimicrobial effects of IFN-γ (18). It has 106 
been confirmed that members of the GBP family, namely GBP1, -6, -7 and -10, all play a key 107 
role in IFN-γ-mediated cell-autonomous immunity against bacterial infection and GBP1, in 108 
particular, is essential for function in macrophage cell lines (19). However, IFN-γ-mediated 109 
immunity to intracellular pathogens appears to be cell type-specific and occurs in a 110 
species-specific manner. IFN-γ stimulated human monocytes and mouse macrophages are 111 
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able to produce high levels of ROS to kill the parasite (15, 16). However, ROS production is 112 
not induced in T. gondii-infected human macrophages (20). Human fibroblasts can also 113 
display IFN-γ-dependent cell-autonomous immunity against T. gondii, although the 114 
involvement of IDO remains controversial (21, 22). Thus, data from animal models may not 115 
directly apply to human toxoplasmosis and the nature/relevance of innate immunity against T. 116 
gondii infection in humans is much less well understood. It is, therefore, useful to understand 117 
the fate of hMSCs (an important cell source for tissue/organ recovery) in T. gondii infection 118 
(23). In addition, the molecular mechanisms through which hMSCs augment 119 
anti-toxoplasmosis remain unclear. 120 
To elucidate the functional contribution of human MSCs to host defense against T. gondii, 121 
we conducted a detailed analysis of gene expression in hMSCs before and after IFN-γ 122 
stimulation using Genome-wide RNA-seq, and generated hGBP1-, hGBP2- and 123 
hGBP5-knockdown hMSC cell lines. hGBP1, but not other hGBPs or IDO knockdown, 124 
partially restored the IFN-γ-dependent anti-T. gondii response in hMSCs. Moreover, we 125 
observed a significant increase in colocalization of endogenous hGBP1 in the PV membrane 126 
of T. gondii-infected cells. These data clearly show that hGBP1 is associated with the 127 
replication of intracellular T. gondii upon IFN-γ stimulation, suggesting an important function 128 
for hGBP1 in the defense against T. gondii.  129 
 130 
Results  131 
The growth of T. gondii in human MSCs is dose-dependently inhibited by IFN-γ 132 
pretreatment. First, we tested the effects of IFN-γ-stimulated human MSCs on T. gondii 133 
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growth. Human MSCs were pretreated with various concentrations of IFN-γ for 48 hr and 134 
then infected with two T. gondii strains (type I strain RH/GFP and type II strain PLK/RED), 135 
respectively. The fluorescence-labeled intracellular parasites were counted microscopically at 136 
multiple time points post-infection, and the inhibition rates of T. gondii growth were 137 
calculated. The growth of T. gondii was found to be dose-dependently inhibited by IFN-γ 138 
pretreatment. In addition, along with IFN-γ incubation time, the inhibition rate also 139 
significantly increased (Fig. 1A). Interestingly, the same concentrations of IFN-γ had stronger 140 
inhibitory effects on the PLK/RED strain than on the RH/GFP strain (Fig. 1B). Furthermore, 141 
the number of parasites per vacuole at 24 hr post-infection (PLK/RED, Fig. 1C) and the ratio 142 
between parasite rosettes and single parasites at 48 hr post-infection (PLK/RED, Fig. 1D) 143 
were significantly lower in IFN-γ-treated hMSCs than in untreated hMSCs (RH/GFP, SI Fig. 144 
1A and B). Representative fluorescence images of intracellular T. gondii growth at 48 hr 145 
post-infection are shown in Fig. 1E (PLK/RED) and SI Fig. 1C (RH/GFP). To exclude the 146 
possibility that the presence of IFN-γ in the culture medium could have a direct effect on 147 
parasites, we assessed the effect of conditioned medium (CM) obtained from 148 
IFN-γ-stimulated MSCs (at 48 hr post-infection), on T. gondii infection. The CM from 149 
pretreated cultures did not have any significant effect on the ability of T. gondii to invade 150 
hMSCs or to replicate, as compared with CM from unstimulated hMSCs (RH/GFP, p = 0.34; 151 
PLK/RED, p = 0.45; SI Fig. 2). These results strongly suggest that human MSCs act against T. 152 
gondii using some intracellular products that can be induced by IFN-γ. 153 
 154 
The anti-toxoplasma activity of human MSCs is not associated with IDO. Previous 155 
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studies showed that in some human cell types (e.g., HeLa cells), IFN-γ stimulation inhibits T. 156 
gondii growth by depletion of tryptophan (Trp), via the activity of IDO (22, 24). To assess 157 
whether inhibiting the IDO activity could affect the proliferation of T. gondii in 158 
IFN-γ-stimulated MSCs, we tested the effects of three IDO-specific inhibitors (DL-1 MT, 159 
D-1 MT and L-1 MT) or excess amounts of Trp, respectively. Our results revealed that both, 160 
inhibiting the IDO activity by 1-methyl-D/L-tryptophan and adding Trp, significantly 161 
decreased the antimicrobial effect against T. gondii in IFN-γ-stimulated HeLa cells (p < 0.001) 162 
(Fig. 2A), confirming that Hela cells rely on IDO-mediated degradation of Trp for their ability 163 
to resist T. gondii infection. In human MSCs, in contrast, Trp and all three different IDO 164 
inhibitors failed to rescue both strains of the parasite from IFN-γ-stimulated growth inhibition 165 
(Fig. 2A and 2B).  166 
To further confirm these observations, we designed siRNAs which targeted three different 167 
regions of the IDO mRNA. Based on the RT-PCR results, we confirmed that they 168 
significantly decreased the expression of IDO stimulated by IFN-γ (by ~90% in hMSCs 169 
treated with siIDO 1 and siIDO 3) (Fig. 2C). As shown in Fig. 2D, siRNA-mediated IDO 170 
knockdown also could not rescue the parasite from IFN-γ-mediated growth inhibition. These 171 
results suggest that the ability of human MSCs inhibiting the growth of T. gondii does not 172 
depend on Trp deprivation or IDO activity. This is in contrast to the results presented from a 173 
previously reported study (9). 174 
 175 
IFN-γ-inducible p65 guanylate-binding proteins (hGBPs) are significantly upregulated 176 
in MSCs. To examine the possible mechanism of activity of human MSCs against T. gondii 177 
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infection, we performed genome-wide RNA-seq to assess the changes in the expression of 178 
host defense related genes of MSCs treated with recombinant IFN-γ (20 ng/mL). Six 179 
sequencing libraries were constructed (three samples from each group). On average, more 180 
than 18 million 50-bp reads were obtained, of which more than 70% of the reads were 181 
aligned to unique locations in the genome, and included more than 17,000 coding genes from 182 
each library. The global transcriptional profiling data will be published elsewhere. MSCs 183 
from three different donors expressed a series of host defense related factors. Through gene 184 
ontology (GO) analysis, we identified 106, 53, 12 and 9 expressed genes (Reads per kilobase 185 
pairs per million (RPKM) value > 5) that were associated with defense responses to viral, 186 
bacterial, protozoan and fungal infections, respectively (SI Fig. 3). Previous reports have 187 
demonstrated that mouse GBPs are involved in T. gondii growth inhibition (18, 25, 26). 188 
Accordingly, we analyzed the expression of GBP family members in human MSCs before 189 
and after IFN-γ treatment. As shown in supplementary Figure S4, the RPKM values for 190 
hGBP1, -2, -3, -4 and -5 significantly increased, qRT-PCR results further showed that the 191 
expression levels of hGBP1, -2, -4 and -5 were increased up to 100-fold following IFN-γ 192 
treatment (Fig. 3A). The relative abundances of the mRNAs for hGBP1, -2 and -5 compared 193 
with β-actin were significantly higher than that of hGBP3 and hGBP4 (Fig. 3B). Western 194 
blotting revealed that the protein expression levels of hGBP1, -2 and -5 were greatly 195 
increased after IFN-γ stimulation (Fig. 3C). These top three most highly expressed hGBPs 196 
(hGBP1, -2 and -5) were selected for further testing for their potential roles in human MSC 197 
activity against T. gondii infection .  198 
In mice, MSCs rely on nitric oxide (NO) produced by iNOS to protect themselves (9). 199 
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Interestingly, we found that the expression of iNOS (NOS2) and human IRG genes were 200 
close to zero in MSCs both before and after stimulation with IFN-γ. This was also the case 201 
for the constitutive NOS (NOS1 and NOS3) genes, further supporting the notion that iNOS 202 
shows no increase in expression following stimulation. Using reverse transcriptase 203 
quantitative PCR and western blotting, we also observed no iNOS expression in human 204 
MSCs. To further confirm these results, using the iNOS-specific inhibitor (NGMMA), we 205 
revealed that inhibiting the iNOS activity did not influence the action of MSCs against T. 206 
gondii (SI Fig. 5). Taken together, our results indicate that the ability of human MSCs to 207 
inhibit the growth of T. gondii does not depend on iNOS. 208 
 209 
Generation of hGBP knockdowns in human MSCs. Stable hGBP1-, hGBP2- and 210 
hGBP5-knockdown hMSC cell lines were generated using specific short hairpin RNA 211 
(shRNA) transcription cassettes and confirmed by RT-PCR (Fig. 4A and 4B) using 212 
gene-specific primers (SI Table 1) and Western blotting (Fig. 4C). To test the characteristics 213 
of the three kinds of shGBP-MSCs, FACS was used to analyze hMSC surface markers. 214 
Compared with wild-type human MSCs, all transduced cells expressed the same panel of 215 
surface markers, exhibiting positive expression of CD29, CD44, CD73, CD90, D166 and 216 
CD105, while detectable expression of the hematopoietic stem cell markers CD34 and CD45 217 
was not found. Representative FACS results for shCtrl- and shGBP1-MSCs are shown in SI 218 
Fig. 6A. Our results clearly indicated that transduced cells maintained the cell-surface marker 219 
phenotype of human MSCs.  220 
To demonstrate that these cells still maintain their multipotency, they were cultured under 221 
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conditions that could promote their differentiation into osteogenic or adipogenic lineages. 222 
Following culture in osteogenic medium for 2 weeks, the shGBP-MSCs were induced to 223 
differentiate into osteoblasts as confirmed by strong Alizarin Red S staining (SI Fig. 6B). 224 
Similarly, oil red O staining revealed the presence of lipid droplets in the cytoplasm of 225 
shGBP-MSCs on day 21 after adipogenic differentiation (SI Fig. 6C). The knockdown of 226 
hGBPs did not alter the proliferative properties of human MSCs, which was veriﬁed by 227 
CCK8 assays (p = 0.37, SI Fig. 6D). Cell survival analysis showed that the cells cultured with 228 
serum-deprived conditions for 48 hours only produced a mild, non-significant, increase in the 229 
death rate which was similar to that found in shGBP1-MSCs (7.82% ± 0.94%) and 230 
shCtrl-MSCs (7.31% ± 0.73%; p = 0.21) (Fig. 4D). Similar features of sustained 231 
multipotency were also observed in shGBP2- and shGBP5-MSCs. These results 232 
demonstrated that the osteogenic and adipogenic differentiation, proliferation and survival 233 
potential of shGBP-MSCs showed no observed differences from the control human MSCs.  234 
 235 
hGBP1 is a key factor for inhibition of T. gondii growth in human MSCs stimulated by 236 
IFN-γ. To investigate whether GBP family members contribute to the IFN-γ induced 237 
antimicrobial effect of MSCs, we examined the effect of GBP knockdown in MSCs on the 238 
growth of T. gondii. Remarkably, compared to control cells, inhibition of T. gondii growth 239 
was rescued in shGBP1-MSCs (Fig. 5A, Upper, RH/GFP; Lower, PLK/RED) at 24 hr 240 
post-infection. Specifically, using the RH/GFP and PLK/RED strains, we found the inhibition 241 
rates of T. gondii growth in MSCs at 5 and 20 ng/ml of IFN-γ were significantly reduced by 242 
shGBP1, compared with control MSCs (Fig. 5B). In contrast, there was no obvious difference 243 
13 
between control cells and shGBP2- or shGBP5-MSCs at 24 hr post-infection (Fig. 5D). Thus, 244 
our studies demonstrate that hGBP1 may play a major role in inhibiting T. gondii growth in 245 
IFN-γ stimulated human MSCs, in contrast to hGBP2 and hGBP5 that do not.  246 
 247 
Human GBP1 is recruited to the parasitovorous vacuole during T. gondii infection. 248 
Recruitment of mouse GBPs to the PV was reported to be essential for the replication control 249 
of T. gondii (18, 25, 26). To explore the role of hGBP1 in human MSCs, we used 250 
immunofluorescence to assess its intracellular localization after T. gondii infection. 251 
Endogenous hGBP1 was observed in ~10% of vacuoles belonging to IFN-γ-stimulated MSCs 252 
infected with RH/GFP strain at 3 hr post-infection, but only 3% in the corresponding 253 
non-stimulated MSCs (Fig. 6A). A significantly higher percentage of PVs staining positive for 254 
hGBP1 was found in the cells infected with PLK/RED strain (Fig. 6B). This could potentially 255 
explain the stronger inhibitory effect of MSCs on PLK/RED versus RH/GFP strain. 256 
Collectively, these data indicated that the accumulation of hGBP1 on the PV membranes of 257 
IFN-γ-stimulated hMSCs could significantly inhibit the replication of T. gondii.  258 
259 
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Discussion  260 
As an obligatory intracellular protozoan parasite, T. gondii is protected by the plasma 261 
membrane of the host cell, and is thus able to escape from most antibody-based immune 262 
responses (12). Therefore, the host’s innate immune response is largely responsible for 263 
controlling T. gondii infection. Although numerous studies have demonstrated that T. gondii 264 
can grow in various somatic cells from warm-blooded animals and humans in vitro, the 265 
related disease condition is not commonly found in vivo. Previous studies have shown that an 266 
IFN-γ-mediated response against T. gondii infection appears to act in a cell type-specific and 267 
species-specific manner, e.g. non-lymphocytes shown in SI Fig. 7. In mice, astrocytes can use 268 
IRGs to restrict T. gondii infection; mMSCs use iNOS to produce NO; and skeletal muscle 269 
cells use both mechanisms (27). The mGBPs may also critically contribute to fighting T. 270 
gondii replication in vivo (18).  271 
However, many studies in animal models show significant differences from humans, and 272 
vast differences have been observed between immune and somatic cells of patients infected 273 
with T. gondii (14-22). High IDO activity which could result in the depletion of Trp is 274 
considered a key weapon against T. gondii growth in human ﬁbroblasts treated with IFN-γ, 275 
but it does not appear to occur in mouse ﬁbroblasts (20, 28, 29). Human MSCs treated with 276 
IFN-γ were found to exhibit an IDO-mediated antimicrobial effector function against various 277 
pathogens suggesting a similar mechanism which might be used to curtail T. gondii (9). Our 278 
results, however, have indicated that IDO is not a main factor in the ability of human MSCs 279 
to inhibit the growth of T. gondii (Fig. 2D). 280 
The iNOS-mediated production of NO is a well-known molecular effector against 281 
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pathogens in the innate immune responses of various animals, including mMSCs (9), skeletal 282 
muscle cells (27), and also in vivo (15, 30, 31). However, a previous study reported that iNOS 283 
protein expression was not detectable in human MSCs (9). Consistent with these results, our 284 
data also showed that MSCs derived from IFN-γ-stimulated human bone-marrow neither 285 
express any detectable level of iNOS RNA nor inhibition by any iNOS activity. Therefore, it 286 
is highly possible that NO is not the main molecular effector against replication of T. gondii 287 
in human MSCs stimulated by IFN-γ. 288 
It has been reported that an IRG protein-based resistance mechanism is essential to control 289 
T. gondii replication in mice (17, 27). Numerous IRGs were found to converge on vacuoles 290 
containing T. gondii in IFN-γ-activated mouse macrophages, ﬁbroblasts, and astrocytes 291 
(32-34). IRGm in mouse is a membrane marker for host cell self-recognition that is used to 292 
regulate the IRG pathway (35) and other IRGs such as the glycine-lysine-serine motif 293 
containing IRGs (also known as GKSs). Mouse IRGs were found to cooperate with mGBPs 294 
in acting against T. gondii infection (13, 14, 18). These findings suggested that mGBPs and 295 
mIRGs could play important roles in the IFN-γ-dependent, autonomous cellular control of 296 
toxoplasmosis. Furthermore it can be predicted that these protein families could play broader 297 
roles in the host defense systems of murine cells. To our surprise, however, only 298 
one complete IRG (hIRGm) is present in the human genome and it lacks the necessary IFN-γ 299 
induction element (33). In fact, based on our work, we also did not observe the up-regulation 300 
of any hIRGs in our RNA-seq experiments. Our data provide further evidence to suggest that 301 
hIRGm has little (if any) activity against T. gondii infection in humans at least in the case of 302 
hMSCs. Without the cooperation of hIRGm, hGBPs, if present, may be sole contributors to 303 
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anti-toxoplasmosis activity. 304 
In a similar manner to mIRGs, mGBPs belong to the IFN-inducible GTPase family. Kim et 305 
al. reported that mGBPs (at least mGBP1 and mGBP7) participated in antibacterial responses 306 
by recruiting host defense proteins, including phagocyte oxidase, antimicrobial peptides, and 307 
autophagic effectors within macrophages and mGBP1-/- mice (19). A recent report showed 308 
that mGBP2 and mGBP5 could promote bacteriolysis by controlling the activation of the 309 
inflammasome protein, AIM2, in mouse bone marrow–derived macrophages (36). In human 310 
cells, hGBP1 shows one of the highest induction levels in response to IFN-γ stimulation (37). 311 
This has been shown to be associated with viral infections, inflammatory bowel diseases, 312 
glioblastoma and cutaneous lupus erythematosus (38-41).  313 
In the case of toxoplasmosis, previous studies demonstrated that mGBP1, -2, -3, -6, -7, and 314 
-9 were recruited to T. gondii-containing PVs in IFN-γ-activated mouse embryonic fibroblasts 315 
or RAW 264.7 macrophages (42). Recently, a mGBP cluster on chromosome 3 (comprising 316 
the genes encoding mGBP1, -2, -3, -5, and -7) was found to cooperate with mIRGb6 and 317 
mIRGb10 during toxoplasmosis (18). Mice defective in p65 GTPases were highly susceptible 318 
to T. gondii infection and GBPs-deleted in chromosome 3 aneuploid macrophages were 319 
defective in IFN-γ-mediated inhibition of intracellular parasite growth (18). The recruitment 320 
of mGBP2 to T. gondii-containing PVs is essential for a cell’s ability to control T. gondii 321 
replication (25). Furthermore, recruitment of mGBP1 to PVs is associated with vesiculation 322 
and rupture and thus also protects against T. gondii infection (26). Both mGBP1 and mGBP2 323 
have been shown to form tetramers and may also hetero-oligomerize to cooperatively activate 324 
GTPase activity (25). 325 
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The hGBP1, -2 and -3 proteins are paralogs of mGBP1 and mGBP2, and both hGBP1 and 326 
mGBP2 show isoprenylation, which targets proteins to intracellular membranes and/or 327 
facilitates protein/protein interactions (43). Such findings suggest that these GBPs may play 328 
similar roles in protecting human and mouse cells against T. gondii infection. Our present 329 
data clearly show that hGBP1 is recruited to T. gondii PVs (Fig. 6A and 6B) and provides 330 
additional evidence that hGBP1 plays a role similar to that of mGBP1/2. Interestingly, our 331 
RNA-seq and RNAi data showed that hGBP1, not hGBP2, is the main responder in 332 
IFN-γ-stimulated human MSCs. Thus, hGBP1 is unlikely to interact with hGBP2 to execute 333 
this protective function. The third paralog, hGBP3, is also not likely to be a main effector, as 334 
its depletion showed little change. Thus, hGBP1 in human MSCs stimulated by IFN-γ could 335 
be a functional homodimer in the innate immune response. 336 
Recently, Haldar et al. reported that the deposition of mGBPs on T. gondii-containing 337 
vacuoles needed IRG protein-dependent ubiquitination of PVs after priming their host cells 338 
with IFN-γ (44). The recruitment of hGBPs to the membranes of T. gondii-containing PVs is 339 
regulated by the autophagic protein, ATG16L1, in IFN-γ-stimulated human 340 
fibroblast-like (HAP1) cells (45). Here, using both the non-cyst and cyst forming strains 341 
(RH/GFP and PLK/RED) of T. gondii (46), we observed the recruitment of endogenous 342 
hGBP1 to T. gondii-containing PVs at 3 hr post-infection in IFN-γ-stimulated human MSCs 343 
(Fig. 6A and 6B). The signaling pathway that is responsible for recruiting hGBP1 to act 344 
against T. gondii is not yet fully understood. Future studies are needed to examine whether 345 
hGBPs contribute directly to membrane blebbing and the physical disruption of the PV 346 
membrane and/or if they modulate the function of other effectors at this interface. 347 
18 
In summary, we herein define hGBP1 as an important effector molecule in the 348 
IFN-γ-triggered autonomous resistance of human MSCs against T. gondii infection. Our 349 
studies reveal that non-lymphocytes could apply various mechanisms of IFN-γ-triggered 350 
autonomous resistance against T. gondii infection in a cell type-specific and species-specific 351 
manner. Human MSCs offer an excellent example of a somatic cell type that plays a very 352 
important role in the host defense system by providing protection against intracellular 353 
pathogens such as T. gondii. The emerging involvement of MSCs in hematopoiesis and 354 
antimicrobial responses suggest that they are worthy of further development in the context of 355 
novel cellular antimicrobial therapies aimed at reducing infection-related morbidity and 356 
mortality, particularly in immunocompromised patients. 357 
 358 
359 
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Materials and Methods 360 
Cell Culture and Parasite Infection. Human cells were isolated and/or cultured as described: 361 
MSCs (47), human foreskin fibroblasts (HFFs)(48) and HeLa cells (22). Cell proliferation 362 
and cell survival assays were performed as described previously (49). Tachyzoites of T. 363 
gondii RH/GFP (50) and PLK/RED (51) were allowed to naturally egress from the host cells, 364 
and were then quickly harvested using standard procedures (15). The effects of IFN-γ-treated 365 
human MSCs, non-treated human MSCs or conditioned medium (CM) on the growth of T. 366 
gondii (moi = 0.5) were assessed by microscopic counting at different time points 367 
post-infection (18). 368 
 369 
Small Interfering RNA and Short Hairpin RNA Knockdown. In vitro silencing of IDO in 370 
hMSCs was performed as described (47), using three sets of IDO-siRNAs (SI Table 1). The 371 
short hairpin RNA (shRNA) expression vector, pLKOpuro1 (Addgene, USA) was used to 372 
express the control (shCtrl) and hGBP1, -2 and -5-specific shRNAs using specific oligos (SI 373 
Table 1). The helper plasmids, psPAX2 and pMD2.G, were used as lentiviral expression 374 
vectors (Addgene, USA). 293T host cells were used for packaging of the shRNAs. The 375 
MISSION Non-Target pLKOpuro1 control vector (Sigma-Aldrich, USA) was used as a 376 
control (shCtrl). Pools of stably transduced cells were selected using puromycin (2 μg/ml) for 377 
5-7 days. All experiments were performed in puromycin-free media, and each knockdown 378 
was validated by RT-PCR and Western blotting. 379 
 380 
Other methods used in this paper can be found in the Supplementary Information. 381 
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Figure Legends 523 
Fig. 1. IFN-γ-stimulated human MSCs dose-dependently inhibit the growth of T. gondii. 524 
Human MSCs were pretreated for 48 hr with IFN-γ and then infected with T. gondii 525 
(RH/GFP or PLK/RED). (A and B) T. gondii growth inhibition rates were calculated at 6, 12 526 
and 24 hr post-infection (A, RH/GFP; B, PLK/RED). (C) At 24 hr post-infection, the number 527 
of parasites per vacuole in IFN-γ (20 ng/ml)-stimulated hMSCs and unstimulated hMSCs 528 
(controls) were calculated (PLK/RED). (D) At 48 hr post-infection, ratios of intracellular T. 529 
gondii rosettes and PVs containing a single parasite were presented (PLK/RED). (E) 530 
Representative fluorescence images of D. DNA was stained with DAPI. Scale bars represent 531 
20 μm. All presented values are means ± SD, n = 4. Statistical significance was indicated by 532 
comparison with controls. *, p < 0.05; **, p < 0.01; and ***, p < 0.001; N.S., not signiﬁcant. 533 
 534 
Fig. 2. IFN-γ-mediated resistance in hMSCs does not require IDO.  535 
(A and B) Human MSCs or HeLa cells were stimulated with 20 ng/ml of IFN-γ and treated 536 
with 1 mM Trp, or IDO inhibitor (DL-1 MT, D-1 MT, or L-1 MT), or the same volume of 537 
solvent (0.1 M NaOH, control) for 48 h. The cells were then infected with T. gondii (A, 538 
RH/GFP; B, PLK/RED) for 24 hours, and growth inhibition was calculated. (C and D) 539 
Human MSCs were transfected with a control siRNA (siCtrl) or siRNAs targeting three 540 
different regions of IDO (siIDO1, -2, -3) for 24 hr, and treated with IFN-γ and infected with T. 541 
gondii as in A and B. The relative RNA levels of IDO in siIDO- and siCtrl MSCs were 542 
examined by RT-PCR (C). T. gondii growth inhibition rates were calculated at 24 hr 543 
post-infection (D). All results are expressed as the means ± SEM; **, p < 0.01; ***, p < 544 
27 
0.001; N.S., not signiﬁcant; n = 4. 545 
 546 
Fig. 3. The expression levels of hGBPs are significantly upregulated in IFN-γ-activated 547 
MSCs. 548 
Human MSCs were pretreated for 24 hr with IFN-γ (20 ng/ml). (A) qRT-PCR results show 549 
the magnitude of change of hGBP1-5 mRNA expression in IFN-γ-stimulated MSCs 550 
comparison to pre-stimulated cells. (B) Relative mRNA levels of hGBP1-5 in 551 
IFN-γ-stimulated MSCs by RT-PCR with reference to beta-actin controls. (C) The protein 552 
levels hGBP1, -2, and -5 in IFN-γ-stimulated and non-stimulated MSCs, as assessed by 553 
Western blotting. All presented values are given as means ± SEM; n = 3. 554 
 555 
Fig. 4. Characterization of shGBP-MSCs. 556 
Lentiviral shRNAs were used to knock down hGBP1, -2, and -5 (shGBPs), and pLKOpuro1 557 
was used as a control (shCtrl). (A-C) Human MSCs transduced with shCtrl or shGBPs were 558 
stimulated with 20 ng/ml IFN-γ for 48 hr and the knockdown efficiencies of hGBP1 (A), -2 559 
and -5 (B) were assessed by RT-PCR and Western blotting (C). n = 4. (D) MSCs transduced 560 
with shGBPs and shCtrl were cultured in serum-free medium for 48 hours and cell survival 561 
was tested using a LIVE/DEAD viability/cytotoxicity kit. n = 4. The results are expressed as 562 
the means ± SEM; **, p < 0.01; ***, p < 0.001; N.S., not signiﬁcant; PI, propidium iodide 563 
staining. Scale bars represent 20 μm.  564 
 565 
Fig. 5. IFN-γ-mediated resistance in MSCs requires hGBP1. 566 
28 
Human MSCs transduced with shCtrl or shGBPs were stimulated with IFN-γ for 48 h and 567 
then infected with RH/GFP or PLK/RED. (A) Representative fluorescence images of 568 
intracellular T. gondii growth at 24 hr post-infection. IFN-γ, 20 ng/ml; scale bars represent 10 569 
μm. (B and C) The inhibition rates of T. gondii growth in the indicated knockdown and 570 
control cells were calculated at 24 hr post-infection (RH/GFP; PLK/RED). The results are 571 
expressed as the means ± SEM. n = 4. **, p < 0.01; ***, p < 0.001; N.S., not signiﬁcant.  572 
 573 
Fig. 6. Localization of hGBP1 in T. gondii-containing parasitophorous vacuoles.  574 
The subcellular localization of hGBP1 in human MSCs was analyzed by immunostaining. (A 575 
and B) Cells were stimulated with IFN-γ (20 ng/ml) for 48 h, infected with T. gondii for 3 hr, 576 
stained with anti-hGBP1 and DAPI (A, RH/GFP; B, PLK/RED). n = 4. The results are 577 
expressed as the means ± SEM. ***, p < 0.001. Scale bars represent 5 μm. 578 
